The mechanisms underlying the progression of diabetes mellitus and heart failure are closely intertwined, such that worsening of one condition is frequently accompanied by worsening of the other; the degree of clinical acceleration is marked when the 2 coexist. Activation of the sodium-hydrogen exchanger in the heart and vasculature (NHE1 isoform) and the kidneys (NHE3 isoform) may serve as a common mechanism that links both disorders and may underlie their interplay. Insulin insensitivity and adipokine abnormalities (the hallmarks of type 2 diabetes mellitus) are characteristic features of heart failure; conversely, neurohormonal systems activated in heart failure (norepinephrine, angiotensin II, aldosterone, and neprilysin) impair insulin sensitivity and contribute to microvascular disease in diabetes mellitus. Each of these neurohormonal derangements may act through increased activity of both NHE1 and NHE3. Drugs used to treat diabetes mellitus may favorably affect the pathophysiological mechanisms of heart failure by inhibiting either or both NHE isoforms, and drugs used to treat heart failure may have beneficial effects on glucose tolerance and the complications of diabetes mellitus by interfering with the actions of NHE1 and NHE3. The efficacy of NHE inhibitors on the risk of cardiovascular events may be enhanced when heart failure and glucose intolerance coexist and may be attenuated when drugs with NHE inhibitory actions are given concomitantly. Therefore, the sodium-hydrogen exchanger may play a central role in the interplay of diabetes mellitus and heart failure, contribute to the physiological and clinical progression of both diseases, and explain certain drug-drug and drug-disease interactions that have been reported in large-scale randomized clinical trials.
A substantial body of experimental and clinical evidence indicates that glucose intolerance and heart failure are closely intertwined, both pathophysiologically and clinically. 1 Both conditions are highly prevalent in the community, and abnormalities of myocardial and peripheral vascular function are central to both disorders. 2 Both are commonly accompanied by hypertension and coronary artery disease, abnormalities of endothelial function and tissue metabolism, and end-organ derangements-especially involving the heart and kidneys. 1 
PATHOPHYSIOLOGICAL AND CLINICAL INTERPLAY OF DIABETES MELLITUS AND HEART FAILURE
Hyperglycemia predicts the risk of developing heart failure, [3] [4] [5] and heart failure is highly prevalent among individuals with diabetes mellitus and worsens their prognosis. 1 Similarly, a majority of patients with chronic heart failure have diabetes mellitus or prediabetes, 6 and glucose intolerance is associated with the risk of clinical progression and cardiovascular death in patients with established heart failure regardless of whether they have ischemic heart disease. 7, 8 The metabolic derangements of diabetes mellitus often worsen in parallel with the progression of heart failure and improve after its treatment. 9, 10 Conversely, during prolonged follow-up, biomarkers of cardiac injury (which are released in heart failure) rise in parallel with circulating glycosylated hemoglobin (which are increased by glucose intolerance) in people who have neither heart failure nor diabetes mellitus at the time of their initial evaluation. 11 Increased distending pressures in the left ventricle and glomerulus are characteristic of heart failure and diabetes mellitus, respectively, and contribute to worsening cardiovascular and renal function. 12, 13 Accordingly, certain drugs that act (in part) by reducing intracardiac and intraglomerular pressures represent a cornerstone of the management of both disorders (eg, inhibitors of the renin-angiotensin system reduce the progression of renal disease in patients with diabetes mellitus and minimize the progression of cardiac disease in patients with left ventricular dysfunction).
14 Both disorders are distinguished by parallel changes in a broad range of pathophysiological derangements. Both type 2 diabetes mellitus and heart failure are characterized by resistance to the actions of insulin. 15, 16 In both disorders, the reduction in insulin sensitivity is associated with effort intolerance and is improved by training. [17] [18] [19] [20] Yet interventions that improve insulin sensitivity do not improve exercise capacity. 21, 22 Activation of neurohormonal systems (norepinephrine, angiotensin II, aldosterone, and neprilysin) causes structural and functional changes in the cardiovascular system that increase the morbidity and mortality of patients with heart failure, 12, 23, 24 as well as impair insulin sensitivity and contribute to the evolution and progression of microvascular disease in diabetes mellitus (Figure 1 ). [25] [26] [27] [28] [29] Changes in metabolic substrate utilization that are typically seen in diabetes mellitus can alter cardiac performance, 30 and heart failure can impair the peripheral utilization of metabolic fuels, thereby contributing to glucose intolerance. 31 Additionally, patients with both diabetes mellitus and heart failure exhibit derangements in the secretion of and response to various adipokines (adiponectin, leptin, apelin, and adipsin). [32] [33] [34] [35] [36] [37] These cell-signaling proteins may play a role in pancreatic β-cell preservation, 38, 39 and they exert both metabolic and cardiovascular effects that underlie the pathogenesis of both disorders. [39] [40] [41] [42] [43] [44] [45] Adipokines can contribute to both the microangiopathies and cardiovascular effects of obesity in patients with both diabetes mellitus and heart failure (often with a preserved ejection fraction) [46] [47] [48] [49] [50] [51] [52] and may reflect the effects of cachexia in patients with heart failure and a reduced ejection fraction. 53, 54 Oxidative stress, inflammatory biomarkers, and advanced glycation end products are increased in both diabetes mellitus and heart failure and forebode a poor prognosis. [55] [56] [57] [58] [59] Medi- Insulin and glucose (which are increased in type 2 diabetes mellitus) and neurohormonal mechanisms (which are activated in heart failure) stimulate the activity of NHE1 in the heart and vasculature and of NHE3 in the kidneys. The increase in these 2 NHE isoforms causes (1) sodium retention and cardiac hypertrophy, injury, and fibrosis (leading to the progression of heart failure); and (2) impaired insulin sensitivity and worsening glycemia, as well as microvascular and macrovascular complications (leading to the progression of diabetes mellitus). The deleterious effects of NHE1 upregulation in mesangial and tubular cells of the kidney in the pathogenesis of diabetic nephropathy are not shown. NHE indicates sodium-hydrogen exchanger.
cations that are conventionally regarded as antidiabetic agents have been reported to exert both favorable and adverse effects on heart failure, 21, [60] [61] [62] [63] and drugs that are typically identified as treatments for heart failure have both beneficial and deleterious effects on glucose tolerance and insulin sensitivity. 22, [64] [65] [66] 
POTENTIAL ROLE OF THE SODIUM-HYDROGEN EXCHANGER IN THE PATHOPHYSIOLOGY OF GLUCOSE INTOLERANCE AND HEART FAILURE
What biological mechanism might underlie the interplay between glucose intolerance and heart failure? Experimental and clinical studies point to an important role of the sodium-hydrogen exchanger (NHE). 67 The exchange of sodium for hydrogen ions across cell membranes is tightly coupled and mediated by a family of evolutionarily conserved antiporters that consist of ≥9 related isoforms. 68 The distribution of the NHE1 isoform is ubiquitous; it is the predominant isoform in the heart, 69 where it regulates cardiomyocyte pH and volume and protects against ischemia-reperfusion injury. 70, 71 In contrast with the wide distribution of NHE1, the NHE3 isoform is limited to the apical surface of renal and gastrointestinal epithelial cells, where it mediates sodium reabsorption; its action is responsible for a majority of the sodium reuptake that follows glomerular filtration. 72, 73 It is noteworthy that norepinephrine, angiotensin, and aldosterone (which are increased in heart failure) as well as insulin, glucose, and certain adipokines (which are increased in type 2 diabetes mellitus) stimulate the activity of NHE1 in the heart and blood vessels and both NHE1 and NHE3 in the kidneys ( Figure 1 ). Increased NHE activity appears to play an important role in the pathophysiology of heart failure ( Figure 1 ). Upregulation of the NHE3 isoform in the kidneys is a critical mediator of enhanced sodium reabsorption in the proximal tubule 76 and has been implicated in the pathogenesis of fluid retention and peripheral edema as well as resistance to diuretics and endogenous natriuretic peptides. 76, 77 The activity of cardiac NHE1 is markedly augmented in heart failure. 70, [79] [80] [81] [96] [97] [98] The rise in intracellular sodium after NHE1 activation (through the actions of the sodium-calcium exchanger) leads to an increase in intracellular calcium, cardiomyocyte injury, and cardiomyopathy. 71, 75, 81, 99, 100 Inhibition of NHE1 (with cariporide) decreases cardiac necrosis and infarct size; reduces the development of cardiac hypertrophy, fibrosis, remodeling, and systolic dysfunction; and minimizes vascular abnormalities in experimental models of heart failure. [99] [100] [101] [102] [103] [104] Clinical use of cariporide decreases the risk of myocardial injury and cardiovascular death in patients undergoing coronary artery bypass surgery. 105, 106 Similarly, increased expression of NHE isoforms may lead to the development of organ dysfunction and injury in states of glucose intolerance ( Figure 1 ). Upregulation of NHE1 may contribute to the vascular abnormalities of diabetes mellitus through mediation of insulin resistance, 107 hyperglycemia-induced endothelial dysfunction, 88 facilitation of medial hypertrophy and neointimal proliferation, 91, 108 promotion of the atherogenetic properties of monocytes, 94 and increased procoagulant activity. 109 The vascular effects of increased NHE1 activity have been implicated in the microangiopathy of diabetes mellitus (in the kidney, retina, and peripheral nerves) [110] [111] [112] as well as its macrovascular manifestations (ie, accelerated atherosclerosis).
113 NHE1 upregulation also contributes to the cardiac hypertrophy and dysfunction in experimental diabetes mellitus, may underlie the genesis of clinical diabetic cardiomyopathy, and may enhance the dysfunction caused by other etiologies in patients with diabetes mellitus. [114] [115] [116] Increased NHE1 and NHE3 activity in the kidney (stimulated by hyperglycemia, hyperinsulinemia, and adipokines 79, 93, 117, 118 ) may contribute to glomerular hyperfiltration, sodium retention, and mesangial proliferation, [119] [120] [121] [122] [123] [124] [125] [126] all of which are characteristic of diabetic nephropathy. Interestingly, increased NHE1 activity may also play a role in the pathogenesis of cataracts, 127 and increased NHE3 activity has been implicated in the high incidence of uric acid nephrolithiasis in patients with diabetes mellitus.
128

THERAPEUTIC AGENTS FOR DIABETES MELLITUS AND HEART FAILURE CAN EXERT THEIR EFFECTS BY AN INFLUENCE ON SODIUM-HYDROGEN EXCHANGE
If activation of the sodium-hydrogen exchange mechanism contributes to complications of both diabetes mellitus and the progression of heart failure, we might expect that drugs used to treat these 2 disorders to mediate their effects (at least in part) through an inhibitory effect on the NHE (Figure 2 ). An important example is the role played by the renin-angiotensin system in both diseases. Angiotensin II is a major stimulus of NHE1 in both the heart and blood vessels and of NHE1 and NHE3 in the kidney. 77, 85, 129, 130 The adverse actions of angiotensin on systolic and diastolic function appear to be mediated by NHE1, 131, 132 and the deleterious effect of angiotensin II to promote sodium retention is related to its ability to increase NHE3 activity. 77 Angiotensin's stimulatory action on NHE3 may also be responsible for the antinatriuretic effect of insulin as well as the response of renal mesangial cells to hyperglycemia. 79, 133 Interestingly, these stimulatory actions of angiotensin II on NHE isoforms are mediated through the type 1 re-ceptor, [134] [135] [136] [137] and agonism of the type 2 receptor inhibits NHE activity. [136] [137] [138] [139] For all of these reasons, drugs that interfere with the synthesis of angiotensin II or its actions on the type 1 receptor can suppress NHE1 in both the heart and vasculature and both NHE1 and NHE3 in the kidneys. 77, 85, 126, 130 Such effects are likely to underlie the benefits of inhibitors of the renin-angiotensin system in both diabetes mellitus and heart failure.
14 Drugs conventionally used to lower blood glucose in diabetes mellitus have also been shown to affect sodium-hydrogen exchange. Insulin (and drugs that increase insulin sensitivity) may enhance the activity of the NHE. 82, 84, 90, 140 In contrast, hypoglycemic agents that lower blood pressure and produce natriuretic effects (dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and SGLT2 inhibitors) appear to inhibit NHE3 in the kidneys (and some may inhibit NHE1 in the heart).
141-146 Although SGLT2 is not expressed in the heart, 147 SGLT2 inhibitors can inhibit cardiac NHE1, possibly through a binding site for SGLT2 on NHE1. 148, 149 Such an action may underlie reports that SGLT2 inhibitors can ameliorate cardiac injury, hypertrophy, and fibrosis independently of their effects on sodium reabsorption or blood pressure. [150] [151] [152] The effects on NHE1 may be exaggerated in diabetic cardiomyocytes and are not seen if the exchanger is already blocked by cariporide. 148, 149 Drugs conventionally prescribed for the treatment of chronic heart failure can also influence the activity of NHE isoforms, and preexisting activation of NHE1 and NHE3 can modulate the effects of these therapeutic agents in those with left ventricular dysfunction. Increases in NHE3 can cause resistance to the effects of natriuretic peptides, and NHE3 inhibition can potentiate the effects of loop diuretics. 76, 77, 153 Increases in NHE activity can enhance the release of norepinephrine in the heart, 80, 154 and inhibition of NHE1 and NHE3 may contribute to the benefits of β-blockers, particularly those that are nonselective. 83, [155] [156] [157] [158] [159] [160] The increase in cyclic GMP-dependent natriuretic peptides that is seen after neprilysin inhibition acts to inhibit NHE1 in the heart and vasculature as well as NHE3 in the kidneys. [161] [162] [163] [164] [165] [166] [167] [168] NHE inhibition can also attenuate some of the adverse effects of digitalis glycosides without affecting their positive inotropic actions. 169 It is important to note that because aldosterone stimulates NHE1 in the heart and vasculature and both NHE1 and NHE3 in the kidneys, increased activity of the NHE (rather than changes in sodium-potassium exchange) may be the central mechanism by which aldosterone exerts its deleterious effects on the heart and vasculature. 29, 74 , 75, 87, [170] [171] [172] Drugs that block the effects of aldosterone (spironolactone) and distally acting natriuretic agents (amiloride) inhibit both NHE isoforms. 87, [170] [171] [172] [173] [174] [175] [176] This action may mediate the benefits of the 2 drugs in experimental cardiomyopathy and heart failure. 75, 177 The effects on the NHE may also explain why spironolactone and eplerenone (but not other diuretics) ameliorate insulin resistance and reduce glycosylated hemoglobin, even in patients with heart failure and without diabetes mellitus, 178, 179 and why mineralocorticoid receptor antagonism reduces albuminuria in patients both with and without diabetes mellitus in the absence of a direct effect on glomerular arteriolar dynamics.
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THE SODIUM-HYDROGEN EXCHANGER MAY UNDERLIE THE DRUG-DRUG AND DRUG-DISEASE INTERACTIONS REPORTED IN CLINICAL TRIALS
If modulation of sodium-hydrogen exchange represents a mechanism that is central to the pathophysiology and treatment of both diabetes mellitus and heart failure, we might expect to observe certain drug-drug and drug-disease interactions in clinical trials of treatments for these 2 disorders. Drugs conventionally used for the treatment of heart failure and drugs typically prescribed to lower blood glucose in diabetes mellitus can inhibit the activity of both NHE1 in the heart and vasculature and NHE3 in the kidneys. The suppression of NHE3 leads to the inhibition of proximal tubular reabsorption of sodium (and thereby a lowering of blood pressure and natriuresis in diabetes mellitus), whereas the suppression of NHE1 leads to the amelioration of cardiac hypertrophy, injury, and fibrosis and thereby a reduction in the risk of cardiovascular death and hospitalization for heart failure, the 2 major end points in heart failure trials. The potential role of NHE1 in the kidneys is not shown. ACE indicates angiotensin converting-enzyme; ANG, angiotensin; DPP, dipeptidyl peptidase; GLP, glucagon-like peptide; MR, mineralocorticoid receptor; NHE, sodium-hydrogen exchanger; and SGLT, sodium-glucose cotransporter.
Interactions Involving Mineralocorticoid Receptor Antagonists in GlucoseIntolerant Patients With or at Risk of Heart Failure
Mineralocorticoid receptor antagonists reduce the risk of clinical progression in patients with chronic heart failure, but the magnitude of the benefit may not be uniform among subgroups. 184, 185 In the EMPHASIS-HF trial (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure), patients with glucose intolerance (as evidenced by obesity or diabetes mellitus) were particularly likely to show a reduction in morbidity and mortality with treatment ( Figure 3) . 186, 187 Similarly, in the TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist), which looked at patients with heart failure and a preserved ejection fraction, patients with obesity were more likely to exhibit favorable effects on the risk of cardiovascular death and hospitalization for heart failure with spironolactone than individuals without obesity. 188 The observations of an enhanced effect in patients with obesity might be related to their increased production of aldosterone. 189 However, this drug-disease interaction may also be explained by an action of obesity and insulin to enhance NHE activity, 82, 84, 93 which is then blocked by mineralocorticoid receptor antagonists. 74 Similarly, SGLT2 inhibitors reduce the risk of the development of heart failure in patients with diabetes mellitus; such an effect has been seen in large-scale trials with both empagliflozin and canagliflozin. 62, 63 In the 2 trials, the magnitude of the benefit on heart failure events was >2 times as large as that on myocardial infarction and stroke. These findings cannot be explained by an action of these drugs on glycemic control 62,67 but may be linked to an ability of SGLT2 inhibitors to interfere with both NHE1 and NHE3. 67, 145, 147 Thus, these drugs may be particularly effective when both isoforms are upregulated, as when heart failure and diabetes mellitus coexist. 67 Conversely, the benefits of SGLT2 inhibition may be minimized if the NHE is already inhibited. In the large-scale cardiovascular trial with empagliflozin (EMPA-REG Outcomes [Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes]), the benefit on heart failure events was attenuated in patients who were receiving spironolactone at the start of the study (Figure 3) . 190 This drug-drug interaction could be discerned, although only a small fraction of the patients in the trial were taking a mineralocorticoid receptor antagonist. Such an interaction might be more important in ongoing trials of SGLT2 inhibitors in heart failure because a majority of participants in these studies are expected to be receiving spironolactone or eplerenone. 67 If the NHE is already suppressed by a mineralocorticoid receptor antagonist, then little additional benefit might be seen with SGLT2 inhibitors (especially when glucose tolerance is normal) if their effects are primarily mediated through interference with the NHE.
Parallelism and Synergy of the Effects of SGLT2 Inhibitors and Inhibitors of the Renin-Angiotensin System on Renal Function in Patients With Diabetes Mellitus
In patients with diabetes mellitus, inhibition of the renin-angiotensin system and inhibition of SGLT2 have strikingly similar patterns of effect on renal function. With both classes of drugs, initiation of treatment results in an immediate but transient decrease in the glomerular filtration rate, which is then followed by a Figure 3 . Drug-drug and drug-disease interactions influencing the risk of cardiovascular events after NHE-1 and NHE-3 inhibition in patients with heart failure and glucose intolerance. NHE modulation is central to the pathogenesis and treatment of both diabetes mellitus and heart failure, and both SGLT2 inhibitors and mineralocorticoid receptor antagonists may exert clinical benefits by NHE1 and NHE3 suppression. (Interference with the actions of aldosterone on NHE1 in the kidney may also attenuate the pathogenesis of diabetic nephropathy.) In both the EMPHASIS-HF trial (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) of eplerenone in heart failure and a reduced ejection fraction and the TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist) of spironolactone in heart failure and a preserved ejection fraction, patients with glucose intolerance (as evidenced by obesity or diabetes mellitus) were particularly likely to respond favorably to mineralocorticoid receptor antagonism (red-shaded semicircle). Similarly, in the EMPA-REG Outcomes trial (Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes), the beneficial effect of SGLT2 inhibition with empagliflozin on heart failure outcomes was attenuated in patients concomitantly treated with spironolactone (blue-shaded semicircle). NHE indicates sodium hydrogen exchanger; and SGLT, sodium-glucose cotransporter.
progressive improvement in renal function during prolonged therapy. [191] [192] [193] Both medications markedly reduce microalbuminuria. 194, 195 Classically, these effects have been attributed to the distinct (but complementary) ways that both types of drugs lower intraglomerular pressures, with SGLT2 inhibitors acting primarily to constrict the afferent arteriole and renin-angiotensin blockers acting primarily to dilate the efferent arteriole. 193 However, glomerular hypertension and its deleterious effects on renal function may be primarily related to the modulation of tubulo-glomerular feedback that results from increases in the proximal tubular reabsorption of sodium; these can be preceded and caused by increases in NHE activity. 124, 196 Both inhibitors of the renin-angiotensin system and SGLT2 inhibitors block the actions of NHE in the kidney and thereby reduce intraglomerular pressure. 67, 124, 193 Furthermore, interference with the NHE1-stimulatory actions of the renin-angiotensin-aldosterone system in mesangial and tubular cells may attenuate the proliferative and fibrotic processes that underlie the pathogenesis of diabetic nephropathy. 171, 172 The interplay of these NHE-dependent mechanisms may explain the interaction of these 2 classes of drugs to additively reduce the risk of nephropathy in patients with diabetes mellitus in the EMPA-REG Outcomes trial.
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Conclusions
The mechanisms underlying the progression of diabetes mellitus and heart failure are closely intertwined, such that worsening of one condition is frequently accompanied by worsening of the other, and the degree of clinical acceleration is particularly marked when the 2 conditions coexist. Activation of NHE1 in the heart and vasculature and of NHE3 in the kidneys may serve as common mechanisms to both disorders and may underlie their physiological overlap.
Both disorders may be ameliorated by inhibition of the renin-angiotensin system, possibly because the effects of angiotensin II on both the heart and kidney may be mediated by stimulation of NHE1 and NHE3, respectively. Drugs used to treat diabetes mellitus may favorably affect the pathophysiological mechanisms of heart failure by inhibiting both NHE isoforms, and drugs used to treat heart failure may favorably affect glucose tolerance and the complications of diabetes mellitus by interfering with the actions of NHE1 and NHE3. The cardiovascular actions of NHE inhibitors may be enhanced when heart failure and glucose intolerance coexist and may be attenuated when they are given concomitantly with other drugs with NHE inhibitory actions. Recognition of the central importance of the sodium-hydrogen exchanger is critical to understanding the interplay of the 2 disorders and the interactions of their treatments. Although drugs that influence NHE1 and NHE3 are already in widespread clinical use, specific targeting of novel drugs to each NHE isoform 108, 197, 198 may represent an important step in the optimal management of these 2 common disorders, especially when they coexist.
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